The Two Biases That Blind Governance: How Consumer-Technology Optimism and Therapeutic Reasoning Both Mistake an Unbounded Process for a Bounded Disease

Governance discourse about longevity technology relies on two analogies that are rarely examined and, on inspection, empirically false. The first imports the cost curve of consumer electronics: if longevity interventions are software-adjacent, they should cheapen and diffuse the way smartphones did. The second imports the disease-treatment paradigm: longevity research is assumed to proceed the way cardiology or oncology proceeds, through discrete, diagnosable conditions with defined endpoints. Both biases are documented, not merely asserted. Pharmaceutical R&D productivity — new drugs approved per billion dollars invested — has fallen roughly eighty-fold since 1950, the inverse of the semiconductor cost curve it is so often compared to. Neither the FDA nor the WHO recognizes aging itself as a treatable condition, which forces every intervention through a regulatory funnel built for bounded pathologies rather than a continuous process. This paper situates both biases within the broader analytical project of Huynh (2026a–j): they are not independent governance failures but institutional artifacts of the Mortality Symmetry Axiom (Huynh 2026c) — the historical condition under which biological death arrived on a schedule capital could not purchase an exemption from, and which gave every regulatory institution that now governs longevity research its foundational categories. Once both biases are corrected, a further and more consequential problem appears. The two clearest historical precedents for defeating unequal access to a scarce, life-extending technology — the 1972 extension of Medicare to dialysis patients, and the global scale-up of HIV antiretroviral therapy through PEPFAR and the Global Fund — succeeded because each had a structural property that aging does not share: a bounded, diagnosable population that could be 1 tested for, counted, and budgeted against. A disease can be ring-fenced. Aging cannot; it is coextensive with the surviving population past a threshold age. This boundary problem is compounded by two mechanisms documented elsewhere in this series: the Symmetric Wound (Huynh 2026e), which establishes that the administrators who would need to design the unprecedented financing model are structurally incapable of impartial design, and the Reform Acceleration Paradox (Huynh 2026a), which establishes that partial solutions concentrate rather than discharge the political pressure organized around remaining exclusions. The three failures — a false cost-curve expectation, a regulatory category blind to its own target, and a financing logic with no precedent for an unbounded population — are not coincidental. They are the same institutional blindspot operating at three different governance layers simultaneously, each inherited from a world in which MSA held and none of the current problems could arise.